Olivier Michielin
Overview
Explore the profile of Olivier Michielin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
256
Citations
16651
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Stefanidis E, Semilietof A, Pujol J, Seijo B, Scholten K, Zoete V, et al.
J Clin Invest
. 2024 Jun;
134(11).
PMID: 38828721
The adoptive transfer of T cell receptor-engineered (TCR-engineered) T cells (ACT) targeting the HLA-A2-restricted cancer-testis epitope NY-ESO-1157-165 (A2/NY) has yielded favorable clinical responses against several cancers. Two approaches to improve...
12.
Wang C, Zeng Q, Gul Z, Wang S, Pick R, Cheng P, et al.
Cell
. 2024 May;
187(11):2690-2702.e17.
PMID: 38723627
The quality and quantity of tumor-infiltrating lymphocytes, particularly CD8 T cells, are important parameters for the control of tumor growth and response to immunotherapy. Here, we show in murine and...
13.
Bugnon M, Rohrig U, Goullieux M, Perez M, Daina A, Michielin O, et al.
Nucleic Acids Res
. 2024 Apr;
52(W1):W324-W332.
PMID: 38686803
Drug discovery aims to identify potential therapeutic compounds capable of modulating the activity of specific biological targets. Molecular docking can efficiently support this process by predicting binding interactions between small...
14.
de Joode K, Mora A, van Schaik R, Zippelius A, van der Veldt A, Gerard C, et al.
J Immunother
. 2024 Feb;
47(5):190-194.
PMID: 38318726
Single nucleotide polymorphisms (SNPs) in the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene, an inhibitor of T-cell priming, are associated with auto and alloimmunity. Studies implied a role for these SNPs...
15.
Barras D, Ghisoni E, Chiffelle J, Orcurto A, Dagher J, Fahr N, et al.
Sci Immunol
. 2024 Feb;
9(92):eadg7995.
PMID: 38306416
Adoptive cell therapy (ACT) using ex vivo-expanded tumor-infiltrating lymphocytes (TILs) can eliminate or shrink metastatic melanoma, but its long-term efficacy remains limited to a fraction of patients. Using longitudinal samples...
16.
Taylor A, McKeown J, Dimitriou F, Jacques S, Zimmer L, Allayous C, et al.
Eur J Cancer
. 2024 Jan;
199:113561.
PMID: 38278009
Background: Anti-PD-1 antibodies and BRAK/MEK inhibitors (BRAF/MEKi) reduce the risk of recurrence for patients with resected stage III melanoma. BRAFV600-mutated (BRAFmut) melanoma patients who recur with isolated disease following adjuvant...
17.
Jacques S, McKeown J, Grover P, Johnson D, Zaremba A, Dimitriou F, et al.
Eur J Cancer
. 2024 Jan;
199:113563.
PMID: 38278007
Importance: Acral (AM) and mucosal melanomas (MM) are rare subtypes with a poor prognosis. In those with advanced disease, anti-PD-1 (PD1) therapy has reduced activity compared to that seen in...
18.
Ringborg U, von Braun J, Celis J, Baumann M, Berns A, Eggermont A, et al.
Mol Oncol
. 2023 Dec;
18(2):245-279.
PMID: 38135904
Analyses of inequalities related to prevention and cancer therapeutics/care show disparities between countries with different economic standing, and within countries with high Gross Domestic Product. The development of basic technological...
19.
20.
Hepner A, Versluis J, Wallace R, Allayous C, Brown L, Trojaniello C, et al.
Eur J Cancer
. 2023 Nov;
196:113441.
PMID: 37988842
Background: Anti-PD-1 therapy (PD1) either alone or with anti-CTLA-4 (CTLA4), has high initial response rates, however 20% of patients (pts) with complete response (CR) and 30% with partial response (PR)...